Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis Pharmaceuticals reports Q1 2026 earnings, discloses non-GAAP metrics
Filed April 29, 2026 · Period ending April 29, 2026 · ~1 min read
Key Changes
-
medium
Ionis announced first quarter 2026 financial results via press release on April 29, 2026. Actual financial figures are contained in the attached press release, not in the 8-K body itself.
Item 2.02 verify on EDGAR → -
low
Company presents non-GAAP results excluding stock-based compensation expense and related tax effects alongside GAAP metrics. Management believes this helps investors assess performance by removing non-cash equity compensation variability.
Item 2.02 verify on EDGAR →
Summary
Ionis Pharmaceuticals filed a routine quarterly earnings announcement for the first quarter ended March 31, 2026. The 8-K itself is procedural, referencing a press release that contains the actual financial results.
The company continues its practice of presenting both GAAP and non-GAAP financial metrics, with the non-GAAP figures excluding stock-based compensation to provide what management views as a clearer picture of operating performance. For retail investors, this is a standard quarterly disclosure with no unusual elements.
The key takeaway is that Q1 results have been announced, but the actual numbers require reviewing the attached press release (Exhibit 99.1). Investors should examine that press release for revenue, earnings, cash position, and any forward guidance. Watch for management commentary on pipeline progress and partnership developments in the full earnings materials.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Ionis disclosed Q1 2026 financial results via press release, presenting both GAAP and non-GAAP metrics excluding equity compensation.
Added in current filing · verify on EDGAR →
On April 29, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
The company announced its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release disclosure. This is a routine quarterly earnings announcement.
Event · Item 9.01 — Financial Statements and Exhibits
Ionis filed an 8-K attaching a press release dated April 29, 2026; no material business event disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated April 29, 2026.
The 8-K attaches a press release dated April 29, 2026 as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature of the announcement cannot be determined from this 8-K alone. Investors should review the attached exhibit for details.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify